Loading candles…
FDC Ltd, founded in 1936, operates in the pharmaceutical industry with a focus on manufacturing and marketing therapeutic formulations and Active Pharmaceutical Ingredients (APIs). The company is recognized as a pioneer in specialized formulations and a leading manufacturer and marketer of Oral Rehydration Salts (ORS), with its flagship brand Electral noted for its prominence in the ORS category. Its business segments include specialized formulations, ORS, and APIs. FDC's product portfolio features pharmaceutical formulations, oral rehydration salts, and active pharmaceutical ingredients. The company serves markets in India and exports to over 50 countries. Its leading brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl, and Mycoderm.
This page is a live market overview for FDC LIMITED (FDC) on the NSE. As a listed security, FDC LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for FDC before placing trades on tick2trade.
As of the latest feed, FDC last traded at ₹369.8 on NSE, down ₹0.2 (0.05%) from the previous close of ₹370. Today's session range is ₹367 – ₹375.85, against a 52-week band of ₹312.95 – ₹527.8. Traded volume today stands at 2.38L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for FDC in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether FDC is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for FDC LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in FDC. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated FDC option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 5 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 27 May 2026 |
| Audited Results - Q4 & FY26 | To consider and approve the Audited Standalone & Consolidated Financial Results of the Company for Quarter and Year ended March 31, 2026 | 27 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and other business matters | 5 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025, dividend and other business matters | 5 Feb 2026 |
| Unaudited Results - FY25 | To consider and approve the unaudited financial results for the period ended September 30, 2025 and other business matters | 5 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 7 Aug 2025 |
| Audited Results - Q4 & FY25 | To consider and approve Audited Standalone & Consolidated Financial Results of the Company for Quarter and Year ended March 31, 2025. | 28 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.